> top > docs > PMC:7536913 > spans > 664-3717 > annotations

PMC:7536913 / 664-3717 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 220-223 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T2 1781-1786 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T3 1845-1849 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T4 1869-1876 Body_part denotes trachea http://purl.org/sig/ont/fma/fma7394
T5 1881-1889 Body_part denotes bronchus http://purl.org/sig/ont/fma/fma7409

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 1781-1786 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T2 1845-1849 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T3 1869-1876 Body_part denotes trachea http://purl.obolibrary.org/obo/UBERON_0003126
T4 1881-1889 Body_part denotes bronchus http://purl.obolibrary.org/obo/UBERON_0002185

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T4 225-232 Disease denotes anthrax http://purl.obolibrary.org/obo/MONDO_0005119
T5 269-279 Disease denotes infectious http://purl.obolibrary.org/obo/MONDO_0005550
T6 318-326 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 386-394 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 1358-1366 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 1772-1794 Disease denotes ischemic heart disease http://purl.obolibrary.org/obo/MONDO_0024644
T10 1781-1794 Disease denotes heart disease http://purl.obolibrary.org/obo/MONDO_0005267
T11 1799-1805 Disease denotes stroke http://purl.obolibrary.org/obo/MONDO_0005098|http://purl.obolibrary.org/obo/MONDO_0011057
T13 1845-1857 Disease denotes lung cancers http://purl.obolibrary.org/obo/MONDO_0008903
T14 1881-1897 Disease denotes bronchus cancers http://purl.obolibrary.org/obo/MONDO_0001672
T15 2015-2023 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T16 2173-2181 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T17 2503-2511 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T18 2877-2885 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T4 573-574 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 611-612 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 628-629 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 659-672 http://purl.obolibrary.org/obo/OBI_0000245 denotes organizations
T8 1146-1147 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 1486-1498 http://purl.obolibrary.org/obo/OBI_0000245 denotes Organization
T10 1781-1786 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T11 1781-1786 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T12 1781-1786 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T13 1781-1786 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T14 1845-1849 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T15 1845-1849 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T16 1881-1889 http://purl.obolibrary.org/obo/UBERON_0002185 denotes bronchus
T17 1953-1956 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T18 2324-2331 http://www.ebi.ac.uk/efo/EFO_0000881 denotes digital
T19 2644-2651 http://www.ebi.ac.uk/efo/EFO_0000881 denotes digital

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T3 173-184 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T4 1232-1237 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T5 2766-2777 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
12 225-232 Species denotes anthrax Tax:1392
13 269-288 Disease denotes infectious diseases MESH:D003141
14 318-326 Disease denotes COVID‐19 MESH:C000657245
15 386-394 Disease denotes COVID‐19 MESH:C000657245
28 1358-1366 Disease denotes COVID‐19 MESH:C000657245
29 1564-1572 Disease denotes Covid‐19 MESH:C000657245
30 1583-1589 Disease denotes deaths MESH:D003643
31 1690-1695 Disease denotes death MESH:D003643
32 1752-1758 Disease denotes deaths MESH:D003643
33 1772-1794 Disease denotes ischemic heart disease MESH:D003324
34 1799-1805 Disease denotes stroke MESH:D020521
35 1845-1857 Disease denotes lung cancers MESH:D008175
36 1869-1897 Disease denotes trachea and bronchus cancers MESH:D009369
37 1925-1931 Disease denotes deaths MESH:D003643
38 2015-2023 Disease denotes COVID‐19 MESH:C000657245
39 2173-2181 Disease denotes COVID‐19 MESH:C000657245
44 2724-2732 Species denotes patients Tax:9606
45 2503-2511 Disease denotes COVID‐19 MESH:C000657245
46 2877-2885 Disease denotes COVID‐19 MESH:C000657245
47 2987-2996 Disease denotes mortality MESH:D003643

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T2 2453-2462 http://purl.obolibrary.org/obo/GO_0007612 denotes learnings

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 1799-1805 Phenotype denotes stroke http://purl.obolibrary.org/obo/HP_0001297
T2 1845-1857 Phenotype denotes lung cancers http://purl.obolibrary.org/obo/HP_0100526

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T7 0-10 Sentence denotes BACKGROUND
T8 11-107 Sentence denotes Previous public health crises have changed medical product development and regulatory practices.
T9 108-289 Sentence denotes These examples include major legislative amendments and creative application of regulatory paradigms to address HIV, anthrax and other bioterrorism threats, and infectious diseases.
T10 290-543 Sentence denotes 1 To address the threat of COVID‐19 and simultaneously ensure continuity of development of non‐COVID‐19 treatments, regulators are providing significant regulatory flexibility while maintaining the high standards for quality, safety, and effectiveness.
T11 544-776 Sentence denotes As Rasmus Hougaard argued in a recent Forbes article, “The heat of a crisis creates a burning platform, propelling organizations and individuals to make pivots and changes that seemed too hard or overwhelming during normal times.” 2
T12 777-961 Sentence denotes Some of the new policies and procedures allowed regulators to completely reprioritize existing high‐priority public health work and reallocate internal resources in unprecedented ways.
T13 962-1081 Sentence denotes Arguably, such changes should be reserved for public health emergencies because they are unsustainable in the long run.
T14 1082-1468 Sentence denotes However, other interim policies have the potential to endure in a “new normal” way of working to better address public health needs (e.g., repurposed drugs and their combinations with novel therapies), while specific risk‐based policies to accelerate development of potential COVID‐19 therapies and vaccines to an unprecedented level might be applied to other life‐threatening diseases.
T15 1469-1615 Sentence denotes The World Health Organization (WHO) reports, as of August 10, 2020, the total number of global Covid‐19 confirmed deaths is approximately 728,000.
T16 1616-1696 Sentence denotes 3 For perspective, this figure is lower than for other leading causes of death.
T17 1697-1932 Sentence denotes For example, WHO reported the leading causes of global deaths in 2016 were ischemic heart disease and stroke, which claimed 15.2 million lives, and lung cancers (including trachea and bronchus cancers), which caused 1.7 million deaths.
T18 1933-2062 Sentence denotes 4 And as the world has witnessed the economic and societal costs associated with COVID‐19, other diseases share similar burdens.
T19 2063-2182 Sentence denotes These data indicate it would be appropriate to apply the same sense of urgency and innovation to areas beyond COVID‐19.
T20 2183-2387 Sentence denotes We are supportive of many of the proposals being discussed by regulators and other groups identifying transformative practices, e.g., use of digital technologies and flexibility in statistical approaches.
T21 2388-2389 Sentence denotes 5
T22 2390-2560 Sentence denotes Here, we provide an industry regulatory perspective on durable learnings and innovation that may emerge from the COVID‐19 experience; they fall into two major categories.
T23 2561-2751 Sentence denotes First would be innovation in clinical trials and regulatory frameworks, enabled by digital technologies that may increase the efficiency and acceptability to both patients and investigators.
T24 2752-3011 Sentence denotes Second is the application of the same level of regulatory urgency, responsiveness, and flexibility in requirements seen with COVID‐19 solutions to other serious life‐threatening and/or debilitating diseases that remain major causes of mortality and suffering.
T25 3012-3053 Sentence denotes These are described in more detail below.